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Abstract 28 
Tamoxifen has been used for many years to target estrogen receptor signalling in breast cancer cells. 29 
Tamoxifen is also an agonist of the G protein-coupled estrogen receptor (GPER), a GPCR ubiquitously 30 
expressed in tissues that mediates the acute response to estrogens. Here we report that tamoxifen 31 
promotes mechanical quiescence in hepatic stellate cells (HSCs), stromal fibroblast-like cells whose 32 
activation triggers and perpetuates liver fibrosis in hepatocellular carcinomas. This mechanical 33 
deactivation is mediated by the GPER/RhoA/myosin axis and induces YAP deactivation. We report that 34 
tamoxifen decreases the levels of hypoxia-inducible factor-1 alpha (HIF-1a) and the synthesis of 35 
extracellular matrix proteins through a mechanical mechanism that involves actomyosin-dependent 36 
contractility and mechanosensing of tissue stiffness. Our results implicate GPER-mediated estrogen 37 
signalling in the mechanosensory-driven activation of HSCs and put forward estrogenic signalling as an 38 
option for mechanical reprogramming of myofibroblast-like cells in the tumour microenvironment. 39 
Tamoxifen, with half a century of safe clinical use, might lead this strategy of drug repositioning. 40 
 41 
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Introduction 55 
The G protein-coupled estrogen receptor (GPER) is a seven transmembrane G protein-coupled receptor 56 
(GPCR) that mediates the acute response to extracellular estrogens(1, 2). Agonists for GPER include 57 
endogenous estrogens such as 17β-estradiol, as well as synthetic compounds such as tamoxifen and 58 
fulvestrant. Tamoxifen is a GPER agonist that has been used in clinics for more than 50 years as hormonal 59 
therapy for breast cancer based on the classical genomic estrogen receptor (ER) signalling pathway, unrelated 60 
to GPER. Interestingly, tamoxifen has also been used in women at risk of developing breast cancer and has 61 
been observed to reduce mammographic density and fibrosis(3, 4). Due to its established pharmacology and 62 
non-toxicity, tamoxifen is well positioned to lead our efforts in exploring novel modes of action for this drug 63 
and investigating the possible clinical benefits of GPER-mediated estrogen signalling.  64 
 65 
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and, regardless of 66 
aetiology, occurs predominantly in patients with cirrhosis, which is characterised by excessive extracellular 67 
matrix (ECM) deposition that presents the ideal environment for promoting tumour formation.  In this 68 
environment, hepatocyte necrosis, inflammation, oxidative stress and hypoxia are responsible for genetic 69 
alterations and deregulation of signalling pathways that promote HCC development(5-7). It is also known 70 
that inflammation in the stroma in HCC can be modulated by estrogens(8).  71 
 72 
Hepatic stellate cells (HSCs) are stroma resident mesenchymal myofibroblast-like cells(9), which initiate and 73 
modulate liver fibrosis by regulating the chemical(10) and mechanical(11) composition of the  ECM.  HSCs, 74 
like other myofibroblast-like cells(12), are highly responsive to mechanical cues, requiring a stiff 75 
microenvironment to become activated and therefore initiate and perpetuate fibrosis. They achieve this by 76 
(i) activating their contractile apparatus to apply endogenous forces to the ECM, and (ii) mechanosensing the 77 
rigidity from their surroundings(13, 14). Both processes, cell contractility and mechanosensing, rely on 78 
activation of the small GTPase RhoA(15, 16). RhoA is essential in maintaining the activated phenotype of 79 
HSCs, by ensuring cell contractility through regulation of ROCK and other modulators of actomyosin(17).  80 
 81 
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Here we report that tamoxifen induces the mechanical deactivation of HSCs via a previously unidentified 82 
mechanism that involves the GPER/RhoA/myosin axis. This inhibits activation of YAP (Yes-associated protein) 83 
and durotaxis in HSCs. We also show that cell contractility and ECM rigidity regulate the levels of HIF-1a 84 
(hypoxia-inducible factor 1 alpha) and LOX (lysyl oxidase) in HSCs, and that tamoxifen suppresses force-85 
mediated regulation of both HIF-1a and LOX. HIF-1a is fundamental for cell survival in hypoxic conditions(18), 86 
as the LOX family regulates collagen crosslinking and ECM architecture and is therefore required for hypoxia-87 
induced metastasis. 88 
 89 
Results 90 
Tamoxifen treatment reduces myosin activation in HSCs via GPER/RhoA signalling 91 
Actomyosin contractility is a key characteristic of activated HSCs, allowing mechanotransduction and force 92 
generation. This behaviour is adaptive in wound healing but promotes fibrosis in HCC(11). Regulation of 93 
actomyosin contractility is achieved through phosphorylation of the regulatory protein myosin light chain 2 94 
(MLC-2). Tamoxifen is a 17β-estradiol mimetic that activates GPER, and has been well characterised in its 95 
ability to selectively modulate estrogen receptors(19). We used immunofluorescence staining to confirm the 96 
presence of GPER and the canonical estrogen receptors alpha and beta (ER-a and ER-b) in HSCs 97 
(Supplementary Fig S1). We also confirmed the levels of expression of GPER in HSCs using 98 
immunoblotting/immunofluorescence and GPER knockdown/overexpression (Supplementary Fig S2-S4). To 99 
assess actomyosin contractility, we determined the levels of active phosphorylated MLC-2 (pMLC-2), as well 100 
as the total MLC-2, in response to 10 day treatment with tamoxifen. We also included conditions with 101 
antagonists against the ER and GPER receptors to explore which receptor tamoxifen acted through. We used 102 
the selective ER antagonist (ICI182780)(20) and the specific GPER antagonist G15(21). For this experiment 103 
and the subsequent ones, ICI182780 and G15 were used simultaneously with tamoxifen treatment. 104 
 105 
Across all 4 conditions (control, tamoxifen, tamoxifen + ER antagonist, tamoxifen + GPER antagonist), the 106 
staining intensity for MLC-2 remained constant, indicating that protein expression was unchanged following 107 
treatment (Fig 1 a, b). Levels of pMLC-2 were significantly reduced in the tamoxifen and tamoxifen + ER 108 
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antagonist conditions compared to control, indicating that tamoxifen greatly reduces MLC-2 109 
phosphorylation, but does not act through the nuclear estrogen receptors. Conversely, tamoxifen + GPER 110 
antagonist showed pMLC-2 staining intensity comparable to the control condition, suggesting that tamoxifen 111 
achieves inhibition of MLC-2 activation through GPER (Fig 1 a, b).  112 
 113 
To further confirm the specific role of GPER, we performed experiments with siRNA to knockdown GPER 114 
expression, in combination with tamoxifen or the estrogen 17 b-estradiol (E2). Treatment was performed for 115 
72 hours since GPER knockdown with siRNA is only stable for this amount of time. We observed that 72 hour 116 
treatment of HSCs with either tamoxifen or E2 led to a decrease in pMLC-2 without affecting MLC-2 117 
abundance, similar to 10 day tamoxifen treatment. Knockdown of GPER with siRNA GPER showed abundance 118 
of pMLC-2 comparable to the control condition, even in the presence of tamoxifen or E2 (Supplementary Fig 119 
S5). This demonstrates that estrogenic signalling, instigated by either tamoxifen or E2, acts through GPER to 120 
reduce MLC-2 phosphorylation.  Likewise, we assessed the effect of tamoxifen on the activation of MLC-2 121 
after 24h treatment and observed that while the total levels of MLC-2 were kept constant, pMLC-2 were 122 
significantly decreased in the tamoxifen group and this effect was mediated by GPER (Supplementary Fig S6). 123 
 124 
RhoA lies upstream of MLC-2 and controls MLC-2 activation(22). We quantified the levels of total RhoA and 125 
active RhoA levels in HSCs under tamoxifen treatment. Both control and 10 day tamoxifen treated conditions 126 
showed similar levels of total RhoA. Control cells exhibited active RhoA levels of around 50% of total RhoA, 127 
significantly higher than in the tamoxifen treated cells where active RhoA levels were around 20% (Fig 1 c). 128 
Taken together, this data suggests that tamoxifen reduces myosin activation via the GPER/RhoA/MLC-2 axis.  129 
 130 
GPER activation in HSCs impairs force generation and increases cell compliance 131 
To further assess the effects of tamoxifen on cell contractility, we used elastic pillars as a form of traction 132 
force microscopy. This technique assesses the individual force applied to fibronectin-coated 133 
polydimethylsiloxane pillars during cell spreading. Using the deflection of each pillar in contact with the cell 134 
and the known Young’s modulus of each pillar in the array, quantitative analysis of force generation was 135 
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achieved. We report the value of mean maximum force, calculated from the mean value of the maximum 136 
force experienced by each pillar with cellular contact during the time of analysis. Control HSCs generated a 137 
mean maximum force of around 3.2 nN, and following 10 day tamoxifen treatment, this mean maximum 138 
force was significantly reduced to around 1.2 nN. When a GPER antagonist was present alongside tamoxifen, 139 
the mean maximum force returned to a value comparable to control and significantly higher than tamoxifen 140 
alone (Fig 2 a, b). Both 72 hour tamoxifen treatment and E2 treatment also significantly reduced traction 141 
forces in HSCs, but force generation was rescued in the presence of siRNA against GPER. Additionally, G1, a 142 
specifically designed GPER agonist(23), reduced traction forces, but did not with GPER knockdown 143 
(Supplementary Fig S7). These results indicate that GPER regulates cell traction forces, with tamoxifen, E2 144 
and G1 all acting as GPER agonists.  145 
 146 
The ability of cells to generate force is also dependent on their rheological properties such as cell stiffness 147 
(24, 25). Drugs that disrupt the cytoskeleton are known to inhibit the activated phenotype of HSCs(26) and 148 
these types of drugs have also been shown to decrease cell stiffness(27). We used atomic force microscopy 149 
(AFM) indentation of HSCs seeded on fibronectin-coated fluorodishes to determine cell elasticity. By 150 
indenting the cells at points between the nucleus and the cell edge, we ensured that our analysis would 151 
accurately assess the contribution of the cytoskeleton to cell elasticity, and would be unaffected by the 152 
nucleus or the underlying substrate.  153 
 154 
We observed that control HSCs had a Young’s modulus around 4.1 kPa, and this was significantly reduced to 155 
around 1.7 kPa with 10 day tamoxifen treatment. However, with a GPER antagonist, tamoxifen was unable 156 
to reduce the Young’s modulus, and cells had an average Young’s modulus similar to the control condition 157 
(Fig 2 c). 72 hour treatment with either tamoxifen, E2 or G1 reduced cell stiffness, but not in the presence of 158 
siRNA against GPER (Supplementary Fig S7). 159 
 160 
GPER activation reduces HSC mechanosensing and YAP activation  161 
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We used magnetic tweezers microrheology to assess the ability of HSCs to respond to external mechanical 162 
forces, as would be experienced surrounded by a rigid stroma. Fibronectin-coated magnetic beads were 163 
attached to cells, and 12 consecutive pulses of equal force were applied with magnetic tweezers. Cells that 164 
displayed mechanosensitivity showed a reduction in bead displacement as the cytoskeleton reinforced 165 
following force application (Fig 3 a). 166 
 167 
We observed that control HSCs showed mechanosensitivity, significantly reducing the displacement of the 168 
bead on the 12th pulse to 71 % of the displacement measured on the 1st pulse. With 10 day tamoxifen 169 
treatment, the 12th pulse had 85% of the displacement measured on the 1st pulse, a value not significantly 170 
different from its first pulse displacement, indicating a reduction in mechanotransduction. Using the GPER 171 
antagonist G15, mechanotransduction was restored to control levels, with the 12th pulse at 68% compared 172 
to the 1st pulse (Fig 3 b).  173 
 174 
The transcriptional regulator YAP is a key cellular mechanotransducer, converting external mechanical signals 175 
into changes in gene expression through its translocation to the nucleus (28). YAP has further been shown to 176 
be essential in the mechanosensitive phenomenon of durotaxis in HSCs (29). We stained control and 10 day 177 
tamoxifen treated HSCs for YAP and assessed the intensity of staining in both the nucleus and cytoplasm. The 178 
ratio between these intensity values represents the level of YAP translocation to the nucleus and therefore 179 
activation. Control HSCs showed increased YAP nuclear localisation compared to 10 day tamoxifen treated 180 
HSCs, suggesting that tamoxifen reduces levels of YAP mediated mechanotransduction (Fig 3 c, d). 72 hour 181 
treatment of HSCs with either tamoxifen or E2 also led to decreased YAP nuclear localisation, with GPER 182 
knockdown rescuing localisation to that of control HSCs (Supplementary Fig S8), indicating the specific role 183 
of GPER in estrogen-mediated YAP deactivation. The expression of the downstream YAP target genes CTGF 184 
and ANKRD1 were reduced in 10 day tamoxifen treated HSCs, in concurrence with the immunofluorescence 185 
data (Fig 3 e). We then performed correlation analysis for the expression profiles of the genes GPER, YAP, 186 
and CTGF using the TCGA (Cancer Genome Atlas) database and found that GPER expression in HCC patients 187 
negatively correlates with the expression of YAP and CTGF (Fig 3 f).   188 
 8 
 
 189 
Tamoxifen treatment induces HSCs deactivation 190 
Force generation and mechanotransduction are the two pillars required for maintenance of the activated 191 
phenotype of HSCs, similar to other myofibroblast-like cells (30, 31). Since we observed tamoxifen to inhibit 192 
these mechanical properties, we assessed whether tamoxifen could promote HSC deactivation. We used 193 
immunofluorescence and qPCR to assess levels of αSMA and vimentin, both markers of the activated 194 
phenotype. We observed a significant decrease in both α-SMA and vimentin with tamoxifen treatment at 195 
both the protein (Supplementary Fig S9) and mRNA (Supplementary Fig S10) levels.  196 
 197 
With GPER knocked down with siRNA for 72 hours, we observed no effect of tamoxifen in reducing the levels 198 
of both markers of quiescence in HSCs (α-SMA and vimentin), though 72 hour treatment by tamoxifen did 199 
decrease these levels. Likewise, treating HSCs with the 17 b-estradiol also downregulated the expression of 200 
α-SMA and vimentin to levels comparable to those observed in the tamoxifen group (Supplementary Fig S9). 201 
These results support the notion that tamoxifen promotes mechanical deactivation in HSCs through 202 
GPER/RhoA signalling. 203 
 204 
Tamoxifen treatment suppresses ECM protein production 205 
A key role of activated HSCs in promoting further fibrosis and disease development is their ability to produce 206 
high levels of ECM proteins for secretion into their microenvironment. Collagen-I and fibronectin are 207 
abundant proteins within the ECM, playing critical roles in the organisation and structural integrity of the 208 
environment, and when overexpressed, can contribute to a pro-tumour microenvironment(32). We used 209 
immunofluorescence to determine both the intracellular expression, and the extracellular secretion, of both 210 
collagen-I and fibronectin. We observed that 10 day tamoxifen treatment significantly reduced the 211 
intracellular and extracellular levels of both collagen-I (Fig 4 a, b, e) and fibronectin (Fig 4 c, d, f). 72 hour 212 
tamoxifen treatment also reduced intracellular collagen-I and fibronectin levels, but could be rescued with 213 
GPER knockdown. E2 treatment for 72 hours also showed the same trend (Supplementary Figure S11). 214 
 215 
 9 
 
Due to the highly contractile phenotype of activated HSCs, and their role in ECM protein production, we 216 
assessed how enhancing contractile ability influenced collagen-I and fibronectin expression. We transfected 217 
control HSCs with constitutively active myosin-2 (pMLC-2) to increase cell contractility, and we observed 218 
significant increases in expression of both collagen-I and fibronectin (Fig 4 g), suggesting a mechanical basis 219 
to transcriptional regulation of both ECM proteins by HSCs. 220 
 221 
We also assessed how changes in matrix rigidity, achieved through fabrication of different rigidity 222 
polyacrylamide (PAA) gels for cell culture, could change the production of collagen-I and fibronectin. A 1 kPa 223 
gel, which approximates the rigidity of healthy liver(33), was used as a soft substrate and we observed that 224 
increasing this rigidity to 25 kPa gave significant increases in collagen-I and fibronectin mRNAs. We further 225 
observed that 10 day tamoxifen treated HSCs on 25 kPa gels showed mRNA levels of collagen-I and 226 
fibronectin comparable to the 1 kPa condition, i.e. significantly lower than the 25 kPa condition (Fig 4 h). This 227 
indicates that tamoxifen inhibits the mechanical signalling pathway that connects external rigidity and 228 
increased ECM deposition. Collectively these results show that increased contractility and ECM stiffness 229 
trigger a transcriptional increase in both collagen-I and fibronectin in HSCs, and that tamoxifen inhibits this 230 
force-mediated activation. 231 
 232 
Tamoxifen treatment mechanically inhibits the HIF-1α/LOX and HIF-1α/LOX-L2 axes 233 
Liver fibrosis in HCC, along with excess consumption of oxygen by hepatocytes, leads to tissue hypoxia and 234 
the survival of cells becomes dependent on expression of hypoxia-inducible factor 1α (HIF-1α) (34). Hypoxia, 235 
through HIF-1α, can regulate expression of ECM protein genes such as fibronectin (35) and collagen-I (36). 236 
HIF-1α has many other downstream targets, including members of the lysyl oxidase (LOX) family. Lysyl 237 
oxidases are copper-dependent enzymes that have fundamental roles in ECM organization in cancer. For 238 
instance, LOX is essential in hypoxia driven metastasis (37) and LOX-L2 is involved in ECM remodelling in 239 
fibrosis(38). 240 
 241 
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Mechanical induction of HIF-1α has also been observed in endothelial cells exposed  to low shear stress (39), 242 
and in the myocardium in response to mechanical stress(40). While hypoxia is the most common method of 243 
HIF-1α activation, upregulation of HIF-1α expression has also been seen in the presence of oxygen, with G 244 
protein-coupled receptors on the cell surface responding to microenvironmental cues (41).  245 
 246 
We observed that levels of HIF-1α are reduced in HSCs following 10 day tamoxifen treatment (Fig 5 a, b).  247 
Furthermore, levels of LOX and LOX-L2 are also reduced with tamoxifen (Fig 5 c, d, e, f), suggesting that the 248 
ability of HSCs to cross-link collagen fibres in the ECM may be affected by tamoxifen treatment. Similarly, 72 249 
hour treatment by tamoxifen or E2 reduced levels of HIF-1α, LOX and LOX-L2, but no reduction was seen with 250 
GPER knockdown (Supplementary Figure S12). 251 
 252 
Notably, we observed that the levels of HIF-1α, LOX, and LOX-L2, are responsive to mechanical cues 253 
independent of tamoxifen-mediated signalling. The mRNA expression of these proteins is increased following 254 
transfection of HSCs with active myosin-2 (Fig 5 g). Similarly, the culturing of HSCs on polyacrylamide gels of 255 
differing rigidities also affected mRNA production. Compared to a 1 kPa substrate, HSCs cultured on a 25 kPa 256 
substrate showed a significantly increased expression of HIF-1α, LOX, and LOX-L2 (Fig 5 h). This suggests that 257 
mechanotransduction alone can drive processes that promote survival under hypoxic conditions. 258 
 259 
When tamoxifen was added to HSCs cultured on the stiff 25 kPa substrate for 10 days, levels of HIF-1α, LOX, 260 
and LOX-L2 were reduced, becoming equivalent to the levels of these species on the soft 1 kPa substrate. To 261 
gain mechanistic insight into tamoxifen-induced downregulation of LOX, LOX-L2, and fibronectin, we used 262 
HIF-1α siRNA to knock down HIF-1α expression. We observed that the mRNA levels of LOX, LOX-L2, and 263 
fibronectin when treated with HIF-1α siRNA were equivalent to the mRNA levels seen with tamoxifen 264 
treatment (Fig 5i and Supplementary Fig S13). When taken together these results suggest that tamoxifen 265 
decreases LOX, LOX-L2, and fibronectin expression via HIF-1α and that the effect of tamoxifen on HIF-1α 266 
levels is mechanically regulated by reducing myosin-2 dependent HSCs contractility and tissue stiffness.  267 
 268 
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Tamoxifen impairs directed migration via GPER signalling 269 
HSCs have been observed to migrate up a stiffness gradient, a process also known as durotaxis and this has 270 
been suggested to be a further step in the perpetuation of fibrosis in the liver (29). Since this process was 271 
shown to be highly dependent on mechanotransduction, and our results here have shown tamoxifen to 272 
inhibit mechanotransduction through GPER, we investigated the ability of tamoxifen to inhibit HSC durotaxis. 273 
 274 
We prepared PAA gels of dual rigidity to assess HSC durotaxis in vitro following a protocol previously 275 
described (29). On these gels, control HSCs moved an average distance in the x-axis (up the stiffness gradient) 276 
of around 70 µm over 5 ½ hours, with an average speed of 0.99 µm/min along their individual paths. 10 day 277 
tamoxifen treated cells and tamoxifen combined with an ER antagonist treated cells both showed no 278 
durotaxis, with significantly reduced cell movement speeds of 0.20 and 0.15 µm/min respectively. When 279 
tamoxifen was combined with a GPER antagonist, durotaxis was rescued (average distance in x axis = 61 µm 280 
over 5 ½ hours) and cell speed became similar to the control condition (0.98 µm/min). (Figure 6 and videos 281 
1-4.) 72 hour treatment of HSCs with tamoxifen or G1 also abrogated durotaxis behaviour, though GPER 282 
knockdown was able to rescue the tamoxifen treated cells, with durotaxis comparable to the control 283 
condition (Supplementary Figure S14 and videos 5-8). These combined results show that tamoxifen inhibits 284 
HSC ability to migrate to stiffer substrates via GPER signalling.  285 
 286 
Discussion 287 
Estrogens regulate a manifold of physiological and pathological processes and although endogenous 288 
estrogen is mainly derived from the ovaries in premenopausal women and mostly regarded as a female 289 
hormone(42), estrogen is also produced in other tissues, such as adipose tissues and arteries in both men 290 
and women(19, 43). Until recently, the field of estrogens was dominated by studies that explored their 291 
transcriptional effects via nuclear estrogen receptors. However, the last decade has witnessed an explosion 292 
of interest in GPER-mediated estrogen signalling.  293 
 294 
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From our results, GPER comes to light as a comprehensive and effective mechanoregulator that targets the 295 
activation of fundamental proteins in cell mechanics such as RhoA(22, 44) and MLC-2 to control force 296 
generation, mechanosensing and durotaxis in hepatic stellate cells. Increased levels of MLC-2 are required 297 
for the ability of stromal cells to remodel the ECM(45) to perpetuate fibrosis(46). Likewise, high levels of 298 
active YAP, a mechanoresponsive transcriptional regulator(28),  are indispensable for the activation of 299 
tumour-associated myofibroblasts in the stroma (47) and we show that YAP is downregulated in tamoxifen 300 
treated HSCs. Due to the similarity of activated HSCs to myofibroblasts, we posit that GPER is therefore likely 301 
to influence the mechanical properties of other stromal cells (fig 7).  302 
 303 
The activation of hypoxia inducible factor 1α (HIF-1α) is required for cell survival under hypoxic conditions. 304 
The dense stroma that surrounds solid tumours limits the accessibility of nutrients and oxygen to cells, 305 
promoting HIF-1α stabilisation (48). The rapid growth of cancer cells within HCC also leads to high 306 
consumption of oxygen, further generating a hypoxic environment (49). Our data suggest that HIF-1α is the 307 
unifying factor through which tamoxifen subsequently reduces the levels of LOX, LOX-L2, and fibronectin in 308 
HSCs. We suggest that HIF-1α may act as a converging point to mechanically regulate the adaptive response 309 
of HCC to hypoxia and the overall architecture of the tumour microenvironment.  We propose that this 310 
mechanical regulation of HIF-1α by tamoxifen in an oxygen-independent manner may result in an effective 311 
reduction of cell fitness to cope with hypoxic condition in HSCs, and potentially in cancer cells as well, leading 312 
to decreasing fibrosis. 313 
 314 
Development of fibrosis relies on positive feedback pathways, including mechanotransduction and ECM 315 
protein deposition(50), and durotaxis (29). The directed migration of cells to stiffer fibrotic areas leads to 316 
further activation by mechanotransduction, leading to an increase in ECM protein production, which in turn, 317 
promotes a stiffer microenvironment(30) that might lead to increased chemoresistance in cancer cells(51). 318 
Durotaxis can also play a role in facilitating cross-talk between cancer cells and activated stromal cells such 319 
as activated HSCs(52) , and therefore the inhibition of directed migration by tamoxifen, combined with its 320 
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ability to induce HSC quiescence, indicates the multiple ways in which tamoxifen could mechanically 321 
influence the tumor-stroma cross-talk. 322 
 323 
Within the liver tissue, HSCs reside within the ECM, a mixture of scaffolding proteins secreted by HSCs, 324 
amongst other stromal cells. Interactions between cells are mostly through paracrine signalling, as well as 325 
interactions with the ECM proteins, rather than direct cell-cell interactions (9). For our in vitro studies, we 326 
used culture activated HSCs seeded on fibronectin-coated glass, a widely employed model which 327 
recapitulates the activated phenotype in vivo with good approximation(10). However, the behaviour we 328 
observe in vitro may well differ from that in vivo, where HSCs are influenced by factors secreted by cancer 329 
cells and other stromal cells, as well as the complex architecture of the ECM(9), which are not present in our 330 
in vitro setup. Further studies with HSCs are therefore necessary for a full comprehension of the role of GPER 331 
in vivo.  332 
 333 
Our work lays the foundations for further studies that could directly influence therapeutic development.  334 
Tamoxifen is a widely used drug in clinics, with well-established pharmacodynamics (53) and safety (54), and 335 
due to the pleiotropic effects of estrogens and the commonality of GPCR signaling pathways, it is possible 336 
that tamoxifen regulates many genes involved in the function of myofibroblast-like cells such as activated 337 
HSCs or cancer associated fibroblasts. This could lead to development of stromal reprogramming strategies 338 
in which GPER agonists could modulate the fibrovascular stroma of HCC to increase vascular density and 339 
perfusion by reducing overall solid stress, achieved through inhibiting expression of collagen and fibronectin. 340 
This would increase intratumoral drug perfusion, while concurrently impeding the adaptive fitness of tumour 341 
and stromal cells to survive under hypoxic conditions (via HIF-1a) and thus promote widespread hypoxic 342 
necrosis. 343 
 344 
Materials and methods 345 
Cell culture and antibodies 346 
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Primary, culture-activated human hepatic stellate cells (HSCs), passage 3-6, (HHStec 5300; ScienCell, 347 
Carlsbad, CA, USA) were cultured in phenol red medium (DMEM-F12 HAM, cat. D6434, Sigma Aldrich) 348 
supplemented with 10% Foetal Bovine Serum (cat. 10500-064, Gibco), 1% Penicillin/Streptomycin (P4333, 349 
Sigma Aldrich, USA), and 1% Fungizone R Amphotericin (15290-026, Gibco). These cells were tested for 350 
mycoplasma contamination. Tamoxifen (Z-4-hydroxytamoxifen, cat. H7904 Sigma- Aldrich, USA) and 17 b-351 
Estradiol (E2) (catalog number E8875, Sigma Aldrich, USA) were prepared in ethanol (stock solution 100 µM). 352 
The specific ER antagonist (ICI182780)(20), GPER antagonist (G15)(21), and specifically designed GPER 353 
agonist(23)  were purchased from Tocris (cat. 1047, 3678, and 3577, respectively). ICI182780, G1, and G15 354 
were prepared in DMSO (stock solution 50 mM). To prevent any estrogenic effects from phenol red, during 355 
the treatment with tamoxifen, E2, or G1, HSCs were transferred to clear medium with no phenol red (DMEM-356 
F12 HAM, cat. D8437, Sigma Aldrich, USA) supplemented with 10% Double Charcoal Stripped Foetal Calf 357 
Serum - DCSS (cat. 02-46-850, First Link, Wolverhampton, UK), 1% Penicillin/Streptomycin (P4333, Sigma 358 
Aldrich, USA), and 1% Fungizone R Amphotericin (15290-026, Gibco, USA). For subsequent experiments 359 
media (without phenol red) and DCSS were used. In all experiments tamoxifen was used at 5 µM, E2 at 0.1 360 
µM. GPER agonist G1 was used at 1 µM. ER and GPER antagonists (ICI182780 and G15) were added 361 
simultaneously with tamoxifen in all experiments, the concentration used for both was 1 µM. This range of 362 
concentrations have been used effectively in previous studies(55). Tamoxifen treatment was done for 72 h 363 
or 10 days. E2 and G1 treatments were conducted for 72h. Media was replenished every 72 hours in all cases. 364 
For GPER and HIF-1a knock downs, siRNA for GPER (Santa Cruz Biotechnology, cat. sc-60743) and siRNA for 365 
HIF-1A (cat. Sc-35561, from Santa Cruz Biotechnology USA), respectively were used to transfect HSCs before 366 
the specific treatment. Human plasma fibronectin (FC010) was from Millipore USA. Antibodies: MLC-2 367 
(Millipore USA, MABT180, 1/200), pMLC-2 /Thr18/Ser19 (Cell Signaling USA, 3674, 1/200), Total RhoA 368 
(Millipore USA, 04-822 USA, WB 1/1000), pRhoA (Abcam UK, ab41435, WB 1/100), YAP (Santa Cruz 369 
Biotechnology USA, sc-101199, 1/100), collagen-I (abcam UK, ab34710, 1/100), fibronectin (abcam UK 370 
ab2413, 1/500), HIF-1 alpha (abcam UK, ab2185 1/200). LOX (Santa Cruz Biotechnology USA, sc-373950, 371 
1/100), LOX-L2 (Santa Cruz Biotechnology USA, sc-66950, 1/50), αSMA (Abcam UK, ab7817, 1/200), Vimentin 372 
(DAKO UK, M0725, 1/100), GPER (abcam UK, ab39742, 1/1000 and 1/2500), GPER (abcam UK, ab154069, 373 
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1/1000). Anti-Mouse HRP (Invitrogen USA, 626580, 1/2,000), Anti-Rabbit HRP (Abcam UK, ab137914, 1/200), 374 
and Anti-Mouse 488 (Invitrogen USA, A11029, 1/400). The GPER plasmid used to overexpress GPER was 375 
obtained from Sino Biological, UK (catalog number HG11264-ACG) and a stop codon was inserted between 376 
the GPER and GFP sequences by site directed mutagenesis. pEGFP-MRLC1 (constitutively active MLC-2) was 377 
a gift from Tom Egelhoff, Addgene USA plasmid #35680. 378 
 379 
Immunofluorescence staining 380 
Cell immunofluorescence staining was done on coverslips coated with 10 μg ml−1 fibronectin (Gibco, 381 
phe0023). Following pertinent treatment cells were fixed with 4% paraformaldehyde (Sigma, P6148) in D-382 
PBS (Sigma, D8537) for 10 min, and then blocked and permeabilized with 0.2% BSA–0.1%Triton (Sigma, 383 
T8787) in PBS for 30 min. After blocking, cells were incubated with primary antibodies prepared in blocking 384 
solution for 1 h at room temperature in a humidified chamber. Then, cells were washed in D-PBS and 385 
incubated with Alexa Fluor 488-conjugated secondary antibodies and Phalloidin (Invitrogen, A22283, 1/1,000 386 
dilution) prepared in PBS for 30 min at room temperature. Finally, coverslips were washed in PBS and 387 
mounted in mounting reagent with 4,6-diamidino-2-phenylindole (Invitrogen, P36931). Immunofluorescent 388 
images were taken with Nikon Ti-e Inverted Microscope (Nikon, Kingston-upon-Thames, United Kingdom) 389 
with NIS elements software. 390 
 391 
RT–PCR 392 
Total RNA was extracted using the RNeasy Mini kit (Qiagen, 74104) and 1 μg of total RNA was reverse-393 
transcribed using the High-Capacity RNA-to-cDNA kit (Applied Biosystems, 4387406) according to the 394 
manufacturer’s instructions. qPCR was performed using the SYBR Green PCR Master Mix (Applied 395 
Biosystems, 4309155) with 100 ng cDNA input in 20 μl reaction volume. RPLP0 expression level was used for 396 
normalization as a housekeeping gene. The primer sequences for were as follow: RPLP0 forward  5'-397 
CGGTTTCTGATTGGCTAC-3' and reverse 5'-ACGATGTCACTTCCACG-3'; CTGF: forward 5ʹ-398 
TTAAGAAGGGCAAAAAGTGC-3ʹ,  and reverse 5ʹ-CATACTCCACAGAATTTAGCTC-3ʹ, ANKDR1: forward  5ʹ-399 
TGAGTATAAACGGACAGCTC-3ʹ and reverse  5ʹ-TATCACGGAATTCGATCTGG-3ʹ, a-SMA: forward 400 
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5ʹCATCATGAAGTGTGACATCG-3ʹ and reverse 5ʹGATCTTGATCTTCATGGTGC-3ʹ; Collagen-I forward  5'-401 
GCTATGATGAGAAATCAACCG-3' and reverse 5'-TCATCTCCATTCTTTCCAGG-3'; fibronectin forward 5'-402 
CCATAGCTGAGAAGTGTTTTG-3'; and reverse 5'-CAAGTACAATCTACCATCATCC-3';  HIF-1A forward 5'-403 
AAAATCTCATCCAAGAAGCC-3';  and reverse 5'-AATGTTCCAATTCCTACTGC-3';  LOX forward-5'-404 
CAACATTACCACAGTATGGATG-3' and reverse 5'-TAGTCACAGGATGTGTCTTC-3'; LOX-L2 forward 5’-405 
GATGTACAACTGCCACATAG-3’; and reverse 5’-GACAGCTGGTTGTTTAAGAG-3’. All primers were used at 406 
300 nM final concentration. The relative gene expression was analysed by comparative 2−ΔΔct method. 407 
 408 
The procedures for the analysis of gene expression using TCGA data, traction forces using elastic pillars, cell 409 
mechanosensing, durotaxis, atomic force microscopy, GLISA, and the statistical analysis can be found in 410 
supplementary methods. 411 
 412 
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 553 
Figure legends: 554 
Figure 1: GPER activation in HSCs suppresses activation of MLC-2. (a) Representative images for 555 
immunofluorescence staining of HSCs, scale bar 50 µm. (b) Quantification of immunofluorescence staining 556 
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for panel a. MFI = mean fluorescence intensity, 12 fields of views with approximately 20 cells per field per 557 
condition. (c) Quantification of total and active RhoA, expressed as percentage of the total RhoA in the 558 
control condition, 3 biological samples analysed in 3 different experiments. All histogram bars represent 559 
mean±sem, **P<0.01,***P<0.001. Anova and Tukey’s test for b and t-test for c.  Three experimental 560 
replicates in all panels.   561 
Figure 2: Tamoxifen treatment impairs traction forces and increases cell compliance in HSCs. (a) Heat maps 562 
representing forces applied by HSCs on top of pillar arrays, scale bar 20 µm. (b) Quantification of average 563 
forces applied by HSCs on pillars. n = 39 cells (control), 34 cells (tam) and 30 cells (tam and GPER antagonist). 564 
(c) Quantification of cell compliance with atomic force microscopy. Cantilevers used had a 15 µm polystyrene 565 
bead attached. n = 60 cells (control), 42 cells (tam) and 90 cells (tam and GPER antagonist). Mann-Whitney 566 
test for significance, ***P < 0.001. All histogram bars represent mean±sem, **P<0.01,***P<0.001. Three 567 
experimental replicates in all panels.  568 
 Figure 3: Tamoxifen treatment suppresses mechanosensing and YAP activation in HSCs. (a) Representative 569 
trace that shows the decrease in the amplitude of oscillation of a bead attached to a cell that can sense 570 
external mechanical stimuli (mechanosensing). (b) Histogram shows relative bead displacement for the first 571 
and last pulse, n = 25 cells (control), 20 cells (tam) and 21 cells (tam and GPER antagonist). (c) Representative 572 
images for immunofluorescence staining of HSCs, scale bar 20 µm. The white arrow indicates YAP nuclear 573 
localization, whereas the yellow arrow shows reduced nuclear YAP localization. (d) Quantification of YAP 574 
nuclear/cytoplasmic ratio, 16 control cells and 16 tamoxifen cells. (e) qPCR levels of YAP downstream genes 575 
CTGF and ANKRD1, normalized to RPLP0 and relative to control, 3 biological samples analysed in 3 different 576 
experiments. (f) Correlation GPER/YAP/CTGF expressions from TCGA database. Data from 492 patients. t-577 
test, *P<0.05, **P<0.01,***P<0.001. Three experimental replicates in all cases.   578 
Figure 4: Tamoxifen treatment inhibits the synthesis and secretion of the ECM proteins collagen I and 579 
fibronectin (FN). (a, c) Representative images for immunofluorescence staining of HSCs, scale bar 50 µm. (b, 580 
d) Quantification of immunofluorescence staining for panel a,c,e,f. Panel b: 16 control cells and 14 tamoxifen 581 
cells. Panel d: 20 control cells and 14 tamoxifen cells. (e,f) Representative images for immunofluorescence 582 
images of secreted collagen I and FN. (g) qPCR levels of collagen I and FN in HSCs, normalized to RPLP0 (60S 583 
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acidic ribosomal protein P0) and relative to control. (h) qPCR levels of collagen I and FN in HSCs, normalized 584 
to RPLP0 and relative to 1 kPa, t-test for b, d, and g; and Anova and Tukey’s test for h. For panels g, h: 3 585 
biological samples analysed in 3 different experiments. All histogram bars represent mean±sem, *P<0.05, 586 
**P<0.01,***P<0.001. Three experimental replicates in all cases.   587 
Figure 5: Tamoxifen treatment mechanically inhibits the HIF-1A/LOX and HIF-1A/LOX-L2 axes. (a, c, e) 588 
Representative images for immunofluorescence staining of HSCs. (b, d, f) Quantification of 589 
immunofluorescence staining for panel a, c, and e. Scale bar is 50 µm for all panels. Panel b: 20 control cells 590 
and 20 tamoxifen cells. Panel d: 12 control cells and 14 tamoxifen cells. Panel f: 12 control cells and 14 591 
tamoxifen cells. (g) qPCR levels of HIF-1A, LOX, and LOX-L2 in HSCs, normalized to RPLP0 (60S acidic ribosomal 592 
protein P0) and relative to control. (h) qPCR levels of HIF-1A, LOX, and LOX-L2 in HSCs, normalized to RPLP0 593 
and relative to 1 kPa. (i) qPCR levels of LOX, and LOX-L2 in HSCs, normalized to RPLP0 and relative to control. 594 
3 biological samples analysed in 3 different experiments. All histogram bars represent mean±sem, *P<0.05, 595 
**P<0.01,***P<0.001. Three experimental replicates in all cases. t-test for b, d, and f; and Anova and Tukey’s 596 
test for g, h, and i.    597 
Figure 6: Tamoxifen treatment inhibits HSCs durotaxis via GPER signalling. (a) Average cell movement 598 
distance on the soft-stiff rigidity gradient compared to single rigidity soft and stiff substrates presented as an 599 
average displacement (positive values indicate directed movement towards stiff substrate, negative values 600 
towards soft substrate and 0 indicates random movement. n = 3 independent experiments. (b) Cell 601 
movement speed on the soft-stiff rigidity gradient compared to single rigidity soft and stiff substrates. (c) 602 
Representation of the average displacements of HSCs. Quantification was done for 75 cells. Three 603 
experimental replicates in all cases.  Results are expressed as mean ± sem. Anova and Tukey’s post hoc tests 604 
were used for the analysis. 605 
Figure 7: Model illustrating the mechanical effect of tamoxifen treatment in HSCs. Tamoxifen activates 606 
GPER and this downregulates the activity of RhoA, which in consequence decreases the levels of pMLC-2 607 
(active form). The decrease in MLC-2 activation leads to suppressing mechanosensing, force generation, and 608 
HSCs ability to mechanically regulate the synthesis of ECM proteins and HIF-1A. 609 
  610 
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Figure 4 
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Figure 5 
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Figure 7  
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